Cancer BiologybioRxivPreprint
The two sides of resistance: aggressiveness and mitotic instability as the Achilles heel of Osimertinib-resistant NSCLC
Paolo Armanetti, Eva Cabrera San Millán, Raffaella Mercatelli…·Giorgia Maroni
This study identifies BMI1 as a driver of Osimertinib resistance in NSCLC by promoting mitotic instability and aggressiveness, and shows that targeting BMI1 with Unesbulin can suppress tumor growth.
DOI 10.1101/2025.09.25.678204